The gene editing market has become increasingly larger in the past few years and is expected to exceed USD 19.45 billion until 2028. This impressive growth is credited to accelerated development of novel CRISPR/Cas9-based genome editing techniques, precise genome editing methods, gene editing revolution due to technological advancements, and the ability to make cite specific modifications. These ongoing factors are creating rife growth possibilities and driving the global gene editing market.
Added to this, the establishment of new cell and gene therapy manufacturing centre, and biotechnology firms undergoing partnerships or receiving high investments have sped up the development of global gene editing market considerably well in the past few years. In the coming years, it is anticipated that the trend would dominate.
However, ethical issues, challenges in efficient delivery of genes and gene editing tools, issues faced while targeting specific cells are the most significant challenges that are likely to hamper the global gene editing market. Perhaps, market participants in the global gene editing space as well as high-end partnerships of the companies with R&D centers are targeting introduction of efficient tools and delivery methods enabling long-term alterations, new breakthroughs going beyond traditional approach to treating diseases. These are opportunities likely to significantly impact the growth of global gene editing market in the upcoming years.
Gene editing is a type of scientific method that is used to edit or change the DNA of living organisms including plants, bacteria, humans, animals, etc. The method that allows scientists to change the DNA of organisms is referred to gene editing. For example, CRISPR-Cas9 gene editing. The global gene editing market is facing internal and external competition. The small and large gene therapy companies are heavily investing and advancing their gene therapy approaches through technological integrations, implementation of modern genetic techniques, active hiring of huge range of expertise, and other strategic initiatives. These factors are anticipated to be growth opportunities for the market players in the global gene editing market.
.png "Global Gene Editing Market 2018-2028 (USD Billion)")
The top companies contributing to the global gene-editing based research and development of innovative genome editing methods are AstraZeneca, OriGene, New England Biolabs, GenScript, Egenesis, Integrated DNA Technologies, Horizon Discovery, Takara Bio, Cellectis, Intellia, Caribou, CRISPR, Precision Biosciences, Editas Medicine, Sangamo, Cibus, Merck, and KGaA among others.
The current upsurge and range of applications of gene editing are majorly contributed by these companies. These companies appear much more optimistic in gene editing given their capital investment and focus on technology. These companies are ranked based on their previous revenues, sales of products and services, R&D initiatives, and other strategic initiatives.
Gene Editing Market Scope
| Metrics | Details |
| Base Year | 2020 |
| Historic Data | 2018-2019 |
| Forecast Period | 2021-2028 |
| Study Period | 2018-2028 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2028 | USD 19.45 billion |
| Segment Covered | Type, Application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
| Key Players Profiled | genome editing methods are AstraZeneca, OriGene, New England Biolabs, GenScript, Egenesis, Integrated DNA Technologies, Horizon Discovery, Takara Bio, Cellectis, Intellia, Caribou, CRISPR, Precision Biosciences, Editas Medicine, Sangamo, Cibus, Merck, and KGaA among others. |
Key Segments of the Global Gene Editing Market
Type Overview, 2018-2028 (USD Billion)
- Zinc finger nucleases (ZFNs)
- Transcription Activator-Like Effector-based Nucleases (TALENs)
- CRISPR-Cas system
Application Overview, 2018-2028 (USD Billion)
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
Regional Overview, 2018-2028 (USD Billion)
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East and Africa
Reasons for the study
- To determine the industry trends in gene editing in humans.
- Identify challenges and underlying opportunities.
- Support your decisions of marketing, strategy, and planning through detailed market study.
- To build competitive intelligence.
What does the report include?
- Market size information for supporting planning and investment decisions of market players.
- Analysis of market through SWOT, PEST, and STEER analysis.
- Brief study of competitive environment and supply chain dynamics of gene editing technology.
- Study of key performance indicators and operational metrics to help market players benchmark against other businesses.
- Historical data analysis of the key drivers of the gene editing technology.
Who should buy this report?
- This report is intended for all the market participants including scientists, researchers, academicians, R&D experts, business executives, etc seeking reliable, thorough researched, up-to-date information for making quick and better business decisions.
The global gene editing market is expected to bounce back from the effect of pandemic and gather maximum revenue in the forecasted years. The industry growth is supported by continued penetration of advanced genomics technology for better editing of DNA of living organisms, rapid investments, and efficiency of gene therapies, better clinical and scientific understanding of gene editing in the people, and significant investments in technology has boosted the market.
Furthermore, faster approval by regulatory authorities, significant investment in technology, several gene editing–based therapeutics, increased filing of investigational new drugs applications, manufacturing improvements, and introduction of promising gene therapies present a long-term growth opportunity for the global gene editing market.
Most importantly, technology integration for better drug delivery and target for specific cells are offering thrice returns on investment. Thus, increasing number of small and large companies are investing in gene editing technology for better clinical and financial outcomes.
Type Segment
Based on different approaches the market of gene editing technology is classified into several segments namely zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALENs), and CRISPR-Cas9 system. The CRISPR-Cas9 system is set to expand substantially in the global gene editing market as it is a unique technology enabling geneticists and medical researchers edit or change genomes.
Application Segment
Based on different approaches the market of gene editing technology is classified into several applications namely biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. The biotechnology & pharmaceutical companies held the maximum market share of global gene editing market as it is offering significant clinical benefits, R&D boost, and introduction of potential gene therapies by biotech and pharma firms.
Among all the key continents in the world, North American region held fairly large percentage of market share of the global gene editing market due to presence of world-class research facilities in leading US institutions, rapid adoption and wide expansion of applications, and innovation in diagnostics and therapeutics for various diseases, etc.